506 Carnegie Center Drive, Suite 400
125 articles with Sandoz
Sandoz collaborates with Civica Rx to help reduce critical generic medicine shortages in US hospitals
Sandoz Inc. today announced it has entered into a long-term agreement with Civica Rx (Civica, Inc.) to manufacture and supply critical injectable generic medicines, to help reduce supply shortages and ensure acute care settings can deliver optimal patient car
Under terms of the deal, Aurobindo would pay $900 million upfront with an additional $100 million in milestone payments. However, in a filing with the Securities and Exchange Commission, the company announced it had terminated that agreement.
The U.S. Department of Justice charged New Jersey-based Sandoz with four counts of conspiring to rig bids and fix prices for generic drugs.
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
Adamas grants Sandoz license for its generic version of GOCOVRI® as of March 4, 2030 – over 12 years post GOCOVRI launch
Ziextenzo (pegfilgrastim) is a long-acting version of filgrastim and is indicated to decrease the incidence of infection in cancer patients.
NDMA is classified as a probable human carcinogen
Sandoz Inc. Issues Voluntary Recall of Ranitidine Hydrochloride Capsules 150mg and 300mg Due to an Elevated Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA), in the Product
To date, Sandoz has not received any reports of adverse events related to use of the product as part of this recall.
Sandoz Inc. voluntarily recalls Losartan Potassium and Ezetimibe in prescription drug bottles in the U.S. due to failure to meet child-resistant closure requirements
Sandoz Inc. today announced a voluntary recall and corrective action notice for particular lots of product distributed in the U.S. in prescription drug bottles because the cap and bottle combination does not meet federal standards for child-resistant packaging, posing a risk of harm if the tablets are swallowed by children
Sandoz' biosimilar to Enbrel was approved in 2016 by the FDA but has remained off the market due to the patent protection surrounding Amgen's blockbuster rheumatoid arthritis treatment.
Sandoz extends SYMJEPI™ (epinephrine) Injection launch to US pharmacies to help improve patient access to life-saving medicine
Sandoz is committed to helping people access high quality healthcare at affordable prices, with strong focus on areas of unmet patient need
Sandoz announced its donation of over 4,000 packs of SYMJEPI™ 0.3 mg Injection for immediate use in free and charity clinics in the US through its collaboration with Americares.
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors
Collaboration covers proposed trastuzumab biosimilar in Phase III development for human epidermal growth factor receptor 2 positive (HER2+) breast and gastric tumors
EirGenix, Inc. Enters Into Global License Agreement for the Commercialization of its Biosimilar Drug EG12014
EirGenix, Inc. announced that it has entered into a license agreement with global generic and biosimilar drug manufacturer Sandoz AG, granting an exclusive license to Sandoz for right of commercialization of EirGenix 's breast cancer biosimilar drug, EG12014 globally with the exception of Taiwan and mainland China.
4/26/2019Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
Maryland-based United Therapeutics said Sandoz has had eight years to ensure it had its own delivery system in place for its generic pulmonary arterial hypertension medication.
United Therapeutics Corporation was named as a defendant, along with Smiths Medical ASD, Inc., in a lawsuit filed in federal court by Sandoz Inc.
Sandoz, a Novartis division and a global leader in biosimilars, today announced resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and Drug Administration (FDA) to address an FDA complete response letter received in June 2016.